BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 10353734)

  • 1. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.
    Nishizaki M; Fujiwara T; Tanida T; Hizuta A; Nishimori H; Tokino T; Nakamura Y; Bouvet M; Roth JA; Tanaka N
    Clin Cancer Res; 1999 May; 5(5):1015-23. PubMed ID: 10353734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.
    Vikhanskaya F; Bani MR; Borsotti P; Ghilardi C; Ceruti R; Ghisleni G; Marabese M; Giavazzi R; Broggini M; Taraboletti G
    Oncogene; 2001 Nov; 20(50):7293-300. PubMed ID: 11704858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
    Harada H; Nakagawa K; Iwata S; Saito M; Kumon Y; Sakaki S; Sato K; Hamada K
    Cancer Res; 1999 Aug; 59(15):3783-9. PubMed ID: 10446996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer.
    Bouvet M; Ellis LM; Nishizaki M; Fujiwara T; Liu W; Bucana CD; Fang B; Lee JJ; Roth JA
    Cancer Res; 1998 Jun; 58(11):2288-92. PubMed ID: 9622060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer.
    Yuan A; Yu CJ; Luh KT; Kuo SH; Lee YC; Yang PC
    J Clin Oncol; 2002 Feb; 20(4):900-10. PubMed ID: 11844810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells.
    Harada H; Nakagawa K; Saito M; Kohno S; Nagato S; Furukawa K; Kumon Y; Hamada K; Ohnishi T
    Cancer Lett; 2003 Feb; 191(1):109-19. PubMed ID: 12609716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo.
    Schuch G; Machluf M; Bartsch G; Nomi M; Richard H; Atala A; Soker S
    Blood; 2002 Dec; 100(13):4622-8. PubMed ID: 12453880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
    Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
    Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
    Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
    Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.
    Zhang WW; Fang X; Mazur W; French BA; Georges RN; Roth JA
    Cancer Gene Ther; 1994 Mar; 1(1):5-13. PubMed ID: 7621238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model.
    Fujiwara T; Cai DW; Georges RN; Mukhopadhyay T; Grimm EA; Roth JA
    J Natl Cancer Inst; 1994 Oct; 86(19):1458-62. PubMed ID: 8089864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer.
    Waku T; Fujiwara T; Shao J; Itoshima T; Murakami T; Kataoka M; Gomi S; Roth JA; Tanaka N
    J Immunol; 2000 Nov; 165(10):5884-90. PubMed ID: 11067949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recombinant adenovirus expressing wild-type p53 is antiagiogenic--implication for lung cancer gene therapy].
    Fujiwara T; Nishizaki M; Tanaka N
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1217-24. PubMed ID: 10945020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
    Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer.
    Wills KN; Maneval DC; Menzel P; Harris MP; Sutjipto S; Vaillancourt MT; Huang WM; Johnson DE; Anderson SC; Wen SF
    Hum Gene Ther; 1994 Sep; 5(9):1079-88. PubMed ID: 7833367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the vascular endothelial growth factor gene is inhibited by p73.
    Salimath B; Marmé D; Finkenzeller G
    Oncogene; 2000 Jul; 19(31):3470-6. PubMed ID: 10918605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
    Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
    Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
    Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
    Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
    Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.